CD40 and neoplasm: It includes CD40 agonists, CSF-1R inhibitors, CD11b agonists, CCR2 inhibitors, BTK inhibitors, and emerging chemokine receptor inhibitors, such as CXCR2 and CXCR4 antagonists, highlighting the diverse immune modulating approaches to reprogram the immunosuppressive tumor microenvironment.